PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: Indication for personalized therapy

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Huang, Yi Teng ^a,b   Li, Fei Fei ^a,b   Ke, Chen ^b   Li, Zhou ^a,b   Li, Zong Tai ^a,b   Zou, Xiao Fang ^a,b   Zheng, Xiao Xuan ^b   Chen, Yu Ping ^a   Zhang, Hao ^a,b  

^a CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Breast cancer; HER2; Methylation; Prognosis; PTPRO

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST SURGERY; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DNA METHYLATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROMOTER REGION; PTPRO GENE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DNA METHYLATION; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PARAFFIN EMBEDDING; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 3; TISSUE FIXATION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84884829150     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-245     Document Type: Article

References (31)

1. Jemal A, et al. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
2. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61-70. 10.1038/nature11412, 3465532, 23000897, Cancer Genome Atlas Network.
3. Cosimo SD, et al. Management of breast cancer with targeted agents: importance of heterogenicity. Nat Rev Clin Oncol 2010, 7(3):139-147. 10.1038/nrclinonc.2009.234, 20125090.
4. Curtis C, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486(7403):346-352. 3440846, 22522925.
5. Van 't Veer LJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-536. 10.1038/415530a, 11823860.
6. Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 2008, 26(1):1-10. 10.1080/07357900701784238, 18181038.
7. Perou CM, et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752. 10.1038/35021093, 10963602.
8. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9(9):631-643. 10.1038/nrc2713, 19701242.
9. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357(1):39-51. 10.1056/NEJMra043186, 17611206.
10. Muthuswamy SK. Trastuzumab resistance: all roads lead to SRC. Nat Med 2011, 17(4):416-418. 10.1038/nm0411-416, 21475230.
11. Seidman A, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20(5):1215-1221. 10.1200/JCO.20.5.1215, 11870163.
12. Wharram BL, et al. Altered podocyte structure in GLEPP1 (Ptpro)-deficient mice associated with hypertension and low glomerular filtration rate. J Clin Invest 2000, 106(10):1281-1290. 10.1172/JCI7236, 381432, 11086029.
13. Aguiar RC, et al. PTPROt: an alternatively spliced and developmentally regulated B-lymphoid phosphatase that promotes G0/G1 arrest. Blood 1999, 94(7):2403-2413.
14. Motiwala T, et al. Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas. Oncogene 2003, 22(41):6319-6331. 10.1038/sj.onc.1206750, 3020652, 14508512.
15. You YJ, et al. Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients. Cancer Lett 2012, 315(2):138-144. 10.1016/j.canlet.2011.08.032, 3248961, 22099875.
16. Ramaswamy B, et al. Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity. Mol Endocrinol 2009, 23(2):176-187. 2646619, 19095770.
17. Motiwala T, et al. Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proc Natl Acad Sci U S A 2004, 101(38):13844-13849. 10.1073/pnas.0405451101, 518843, 15356345.
18. Mori Y, et al. Identification of genes uniquely involved in frequent microsatellite instability colon carcinogenesis by expression profiling combined with epigenetic scanning. Cancer Res 2004, 64(7):2434-2438. 10.1158/0008-5472.CAN-03-3508, 15059896.
19. Motiwala T, et al. Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. Clin Cancer Res 2007, 13(11):3174-3181. 10.1158/1078-0432.CCR-06-1720, 3074612, 17545520.
20. Yu M, et al. Expression profiling during mammary epithelial cell 3D morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2 mediated transformation. Mol Cell Biol 2012, 32(19):3913-3924. 10.1128/MCB.00068-12, 3457532, 22851698.
21. Sebova K, et al. RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Cancer Biomark 2011, 10(1):13-26.
22. Shetty PJ, et al. Regulation of IGF2 transcript and protein expression by altered methylation in breast cancer. J Cancer Res Clin Oncol 2011, 137(2):339-345. 10.1007/s00432-010-0890-z, 20422427.
23. Harbeck N, et al. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol 2008, 26(31):5036-5042. 10.1200/JCO.2007.14.1697, 18711169.
24. Melnikov AA, et al. Array-based multiplex analysis of DNA methylation in breast cancer tissues. J Mol Diagn 2008, 10(1):93-101. 10.2353/jmoldx.2008.070077, 2175548, 18165279.
25. Sunami E, et al. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res 2008, 10(3):R46. 10.1186/bcr2098, 2481494, 18485221.
26. Son KS, et al. Hypomethylation of the interleukin-10 gene in breast cancer tissues. Breast 2010, 19(6):484-488. 10.1016/j.breast.2010.05.011, 20646924.
27. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer 2006, 6(2):107-116.
28. Swift-Scanlan T, et al. Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort. Cancer Biol Ther 2011, 11(10):853-865. 10.4161/cbt.11.10.15177, 3116929, 21383541.
29. Mehrotra J, et al. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res 2004, 10(9):3104-3109. 10.1158/1078-0432.CCR-03-0118, 15131050.
30. Jacob ST, Motiwala T. Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy. Cancer Gene Ther 2005, 12(8):665-672. 10.1038/sj.cgt.7700828, 3028596, 15803146.
31. Ramezani F, et al. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis. Asian Pac J Cancer Prev 2012, 13(2):451-457. 10.7314/APJCP.2012.13.2.451, 22524805.